Adaptimmune Therapeutics (ADAP) Downgraded to “Hold” at BidaskClub

BidaskClub downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a hold rating in a report issued on Wednesday morning.

Several other analysts also recently commented on the stock. Guggenheim began coverage on shares of Adaptimmune Therapeutics in a research report on Monday, September 17th. They set a buy rating for the company. Cowen reaffirmed a buy rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, August 15th. Zacks Investment Research raised shares of Adaptimmune Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 7th. TheStreet downgraded shares of Adaptimmune Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 16th. Finally, ValuEngine raised shares of Adaptimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Monday, July 2nd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $19.33.

Shares of ADAP stock traded down $0.46 during trading hours on Wednesday, hitting $11.08. 8,384 shares of the company were exchanged, compared to its average volume of 495,377. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -13.98 and a beta of 1.06. Adaptimmune Therapeutics has a fifty-two week low of $6.60 and a fifty-two week high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $7.76 million. Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. As a group, equities analysts expect that Adaptimmune Therapeutics will post -1.02 EPS for the current year.

In related news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction on Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, with a total value of $5,010,000.00. The disclosure for this purchase can be found here. Company insiders own 26.47% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bellevue Group AG acquired a new stake in Adaptimmune Therapeutics in the 2nd quarter valued at $711,000. BlackRock Inc. grew its position in Adaptimmune Therapeutics by 2.5% in the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after purchasing an additional 19,765 shares during the period. Dorsey Wright & Associates acquired a new stake in Adaptimmune Therapeutics in the 2nd quarter valued at $6,981,000. Baillie Gifford & Co. grew its position in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares during the period. Finally, Raymond James Financial Services Advisors Inc. grew its position in Adaptimmune Therapeutics by 70.0% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 13,151 shares during the period. 59.32% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Read More: Market Capitalization – What it Means for Investors

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply